ClinicalTrials.gg
RecruitingNCT05760898Updated Nov 18, 2026

Improving Hypertension Control in Rheumatoid Arthritis

An interventional study of Blood pressure intervention arm in Hypertension and Rheumatoid Arthritis, sponsored by Duke University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Duke University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies in Hypertension by Duke University — 8 open to participants now, 9 under way, none of them phase 3. Hypertension · Duke University.

Planned enrollment
32nd of 37
25 · median 140
Started
2026
with 3 others
No phase
34 of 46
4 open now
Registered
37th of 46
by date

Among the 46 studies in Hypertension by Duke University, this one is the 32nd largest by planned enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2026, is one of 34 with no phase, and was the 37th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

8 of the 46 studies in Hypertension by Duke University are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Hypertension by Duke University, or all of them as a file.
02

Study summary

Rheumatoid arthritis (RA) is a autoimmune disease associated with an increased risk of developing coronary artery disease (CAD) and premature death,. Traditional CAD risk factors like hypertension (HTN) are both very common and poorly controlled among RA patients. Patients with RA face significant challenges in controlling HTN. The goal of this project is to identify barriers to HTN care in patients with RA to reduce CAD events.

03

Conditions studied

  • Hypertension
  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years old or older
  • Uncontrolled hypertension
  • History of rheumatoid arthritis
  • Receive both primary care and rheumatology care from Duke Health System

Exclusion criteria

Exclusion Criteria:

  • Age less than 18 years old
  • Healthy volunteers without rheumatoid arthritis and hypertension
  • Do not receive both primary care and rheumatology care from Duke Health System
  • Cognitive impairment with lack the capacity to consent to study participation
  • Pregnant women
  • Prisoners
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Blood pressure intervention arm

    The investigators will recruit 25 RA patients with HTN for the study. Participants will be provided with a home blood pressure monitor, teaching from nursing staff regarding the correct use of the monitor, and a guide to help interpret normal and elevated blood pressure values. Participants will be instructed to obtain and record blood pressure values at least three times per week over the course of 3 months. Every 2 weeks, these results will be sent to the study team, and participants will complete a brief survey regarding other factors that may influence blood pressure control, including RA disease activity (RAPID3 score), pain, current use of acute RA therapies, anti-hypertensive medication use, anti-hypertensive medication adherence, and current perceived barriers to HTN self-management.

    Behavioral: Blood pressure intervention arm

Interventions

  • BehavioralBlood pressure intervention arm

    The intervention will focus on empowering patients to actively participate in their HTN care, facilitating patient-provider communication, and creating a cohesive care team to close the coordination loop for HTN management. This pilot intervention will help achieve these goals by providing participants with home blood pressure monitors and teaching, improving patient-provider communication regarding blood pressure and RA management, and initiating care coordination between rheumatology and primary care providers.

06

What researchers measure

Primary outcomes

  1. Intervention feasibility as measured by participant accrual rates

    Rate at which participants are able to be successfully recruited

    Time frame: 6 months

  2. Intervention feasibility as measured by participant retention

    Percentage of participants who successfully complete the study

    Time frame: 6 months

  3. Intervention feasibility as measured by adherence to blood pressure monitoring

    Percentage of expected blood pressures reported by participants

    Time frame: 6 months

  4. Intervention feasibility as measured by adherence to survey reporting

    Percentage of expected surveys completed by participants

    Time frame: 6 months

  5. Intervention feasibility as measured by sample characteristics

    Description of sociodemographic characteristics of population, rheumatoid arthritis characteristics (eg, duration, medications, severity), and hypertension characteristics (eg, duration, medications, severity)

    Time frame: 6 months

  6. Intervention feasibility as measured by use of resources

    Cost of participant recruitment, education, blood pressure monitors, participant compensation, research coordinator time and cost needed to collect data, and statistical analysis

    Time frame: 6 months

  7. Intervention feasibility as measured by sustainability of data collection procedures

    Financial and time commitments required to successfully collect participant surveys, blood pressure monitoring results, send information to providers, and monitor provider responses

    Time frame: 6 months

  8. Intervention acceptability as measured by qualitative interviews

    Qualitative interviews will be performed at the end of the pilot intervention with all study participants to assess the acceptability of the intervention. Rheumatology and primary care providers caring for study participants will also be invited to comment on the acceptability of the intervention.

    Time frame: 6 months

  9. Perceived appropriateness of the intervention to address the health care disparity in HTN (hypertension) control for Black RA patients as measured by qualitative interviews

    Qualitative interviews will be performed at the end of the pilot intervention with all study participants to assess the perceived appropriateness of the intervention to address the health care disparity in HTN control for Black RA patients. Rheumatology and primary care providers caring for study participants will also be invited to comment on the appropriateness of the intervention.

    Time frame: 6 months

  10. Barriers to and enablers of participating in the intervention as measured by qualitative interviews

    Qualitative interviews will be performed at the end of the pilot intervention with all study participants to assess barriers to and enablers of participating in the intervention.

    Time frame: 6 months

Secondary outcomes

  1. Participant blood pressure values

    Systolic and diastolic blood pressures taken at least three times per week and reported to the study team every 2 weeks for 6 months

    Time frame: 6 months

  2. Participant rheumatoid arthritis disease activity

    Rheumatoid arthritis disease activity self-reported by participants using the RAPID3 score every 2 weeks for 6 months

    Time frame: 6 months

  3. Participant medication use

    Medication use for hypertension and rheumatoid arthritis reported by participants every 2 weeks for 6 months

    Time frame: 6 months

  4. Anti-hypertensive medication adherence

    Participant self-reported adherence percentage to anti-hypertensive medications collected every 2 weeks for 6 months

    Time frame: 6 months

  5. Perceived barriers to hypertension self-management

    Participant self-reported barriers to hypertension self-management collected every 2 weeks for 6 months

    Time frame: 6 months

  6. Provider engagement as measured by response to study team messages

    Frequency and type of provider responses to study team messages

    Time frame: 6 months

  7. Provider engagement as measured by interactions with participants

    Frequency and type of provider interactions with participants after receiving a study team message

    Time frame: 6 months

  8. Care coordination

    Activation of care team members

    Time frame: 6 months

  9. Number of participants with a change in medical therapy

    Changes in anti-hypertensive or RA therapies

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 11 months is below that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2023
First posted
Mar 9, 2023
StartActual
Jan 16, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and contact details
1 update, last Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Minor edits only
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05760898
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Mar 9, 2023
Start date
Jan 16, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 18, 2026

Study contacts

Isaac Smith, MD
Contact
isaac.smith063@duke.edu
919-613-2243

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion